Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24267286 | 0.87 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 | |
| SCHEMBL20086419 | 0.83 | SLC6A4 (0.56) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 | |
| SCHEMBL14704876 | 0.83 | SLC6A4 (0.56) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 | |
| SCHEMBL24136460 | 0.83 | SLC6A4 (0.56) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 | |
| SCHEMBL17633193 | 0.83 | SLC6A4 (0.56) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 | |
| SCHEMBL17633190 | 0.83 | SLC6A4 (0.56) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 | |
| SCHEMBL24267396 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 | |
| SCHEMBL20046785 | 0.79 | SLC6A2 (0.57) | SLC6A2SLC6A3SLC6A4HRH1HTR1A | |
| SCHEMBL30182887 | 0.79 | SLC6A2 (0.57) | SLC6A2SLC6A3SLC6A4HRH1HTR1A | |
| SCHEMBL18610915 | 0.79 | SLC6A2 (0.58) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118546055-A | Preparation method of (1R, 3S, 5S) -3- (4- (5-bromo-2-chlorobenzyl) phenoxy) bicyclo [3.1.0] hexane | 山东科巢生物制药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-10253010-B2 | C-glycoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2019-04-09 | — | — | US | disclosed |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-13 | — | — | US | disclosed |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-13 | — | — | US | disclosed |
| US-9562029-B2 | C-glycoside derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2017-02-07 | — | — | US | disclosed |
| US-9562029-B2 | C-glycoside derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2017-02-07 | — | — | US | disclosed |
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-05-08 | — | — | US | disclosed |
| EP-2725031-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | RDX, C3AR1, C1R | SLC6A2 2963/4885SLC6A3 3028/4885SLC6A4 3671/4885 |
| US-10253010-B2 | C-glycoside derivative | RDX, C1R, C3AR1 | SLC6A2 2955/4885SLC6A3 2832/4885SLC6A4 3582/4885 |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | RDX, C1R, C3AR1 | SLC6A2 2955/4885SLC6A3 2832/4885SLC6A4 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.